Brind.

Kodiak Sciences to Report Phase 3 Daybreak Study Results on September 28

1 report, 1 independent Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Kodiak Sciences announced that it will report topline results from the Daybreak study on Monday, September 28, 2026. The Phase 3 study evaluated two products, Zenkuda and KSI-501, for the treatment of patients with wet age-related macular degeneration. Kodiak Sciences also stated that it is forecasting the availability of relevant data from PEAK in 2026 or 2027.

From prnewswire.com

Why it matters

Some supportBrind's analysis of the reports

The results from the Daybreak study are critical for Kodiak Sciences as a company focused on developing late-stage clinical programs. The outcome of the evaluation of Zenkuda and KSI-501 could influence the company's future commercialization plans and partnerships.

From prnewswire.com

Who's involved

  • Kodiak Sciences Inc.Biotech company conducting the Daybreak Phase 3 study and forecasting future data from PEAK.
  • PEAKChemical company whose data is being forecasted by Kodiak Sciences for future analysis.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped